Medications for Primary Myelofibrosis
5 results
Inrebic (fedratinib hydrochloride)
(Fedratinib Hydrochloride)Celgene Corporation
Usage: INREBIC® is indicated for treating adult patients with intermediate-2 or high-risk myelofibrosis (MF), including primary or secondary forms (post-polycythemia vera or post-essential thrombocythemia).
Jakafi (ruxolitinib)
(ruxolitinib)Incyte Corporation
Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute graft-versus-host disease in patients aged 12 and older. It also treats chronic graft-versus-host disease after failure of one or two prior systemic therapies in the same age group.
Nutropin aq nuspin 5 (somatropin)
(somatropin)Genentech, Inc.
Usage: Nutropin AQ is indicated for treating growth hormone deficiencies in pediatric patients, including growth failure due to inadequate GH, chronic kidney disease, idiopathic short stature, and Turner syndrome. For adults, it replaces endogenous GH in those with adult-onset or childhood-onset growth hormone deficiency.
Ojjaara (momelotinib)
(Momelotinib)GlaxoSmithKline LLC
Usage: OJJAARA is indicated for treating intermediate or high-risk myelofibrosis (MF), including primary and secondary MF (post-polycythemia vera and post-essential thrombocythemia), in adults who have anemia.
Vonjo (pacritinib)
(Pacritinib)CTI BioPharma Corp.
Usage: VONJO is indicated for treating adults with intermediate or high-risk primary or secondary myelofibrosis (MF) with a platelet count below 50 × 10^9/L. Approval is based on spleen volume reduction, with continued approval dependent on confirmatory trial results.